| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $90.4M | -6.5% |
| SG&A Expense | $31.6M | +0.4% |
| Operating Income | -$122.0M | +4.8% |
| Income Tax | $0 | — |
| Net Income | -$104.1M | +4.3% |
| EPS (Basic) | -$1.41 | +11.9% |
| EPS (Diluted) | -$1.41 | +11.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $39.6M | +42.2% |
| Short-term Investments | $236.6M | -1.2% |
| Current Assets | $282.5M | +3.4% |
| Total Assets | $404.2M | -19.4% |
| Current Liabilities | $22.3M | +17.7% |
| Total Liabilities | $91.9M | -1.4% |
| Stockholders' Equity | $312.3M | -23.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$88.7M | +11.0% |
| Capital Expenditures | $1.2M | -72.6% |
| Investing Cash Flow | $100.3M | +177.4% |
| Financing Cash Flow | $141K | -99.9% |
| Free Cash Flow | -$89.9M | +13.6% |